B+
Bull case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
PHAR
Pharming GroupCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The already-granted pediatric approval, Japan launch and Joenja growth could broaden revenue while forthcoming immunodeficiency data create a longer-term development option. That upside depends on patient conversion and confirmatory evidence, not merely regulatory milestones [#PR-2026-09-11] [#PR-2026-08-13] [#PR-2026-09-22].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -1.0.
What can break
Broader PID/CVID efficacy is unestablished; the announced genetically defined PID Phase II findings came from a 13-patient, single-arm study [#PR-2026-09-22].
Momentum
65
Value
61
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.00 · Bull $13.00 · Bear $7.00Analysis 2026-09-30; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $29.96
Why
Momentum65 · Δ7d -
Value61 · Δ7d -1.0
Sentiment42 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -1.0.
Contradictions & invalidation
- • Broader PID/CVID efficacy is unestablished; the announced genetically defined PID Phase II findings came from a 13-patient, single-arm study [#PR-2026-09-22].
- • RUCONEST Q2 revenue declined 10% year over year and its active patient base was 93% of the year-earlier level amid competition [#PR-2026-07-30].
- • RUCONEST volume pressure, the $30 million revenue-guidance reduction, lower Q2 operating profit and abrupt CEO change could offset Joenja progress.
Catalyst clock
2026-10-17
Detailed leniolisib Phase II data at ESID
Lead driver: Value · See fundamentals
Momentum
65
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
61
47% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
-1.4
Sentiment
42
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 64.5 / Value 60.9 / Sentiment 42.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-30. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$784.84M
Beta
-0.24
Shares Out
70.78M
P/E (TTM)
411.2
P/S (TTM)
3.16
P/FCF (TTM)
21.75
Rev YoY
-4.6%
EPS YoY
-66.8%
Gross Margin
+84.8%
Op Margin
+6.1%
Net Debt
-$64.09M
Current Ratio
3.01
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data